Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

被引：0
|
作者：
Sinclair, Rodney [1 ]
Thaci, Diamant [2 ]
Vender, Ronald [3 ]
de Rie, Menno [4 ]
Conrad, Curdin [5 ]
Soung, Jennifer [6 ]
Strober, Bruce [7 ,8 ]
Wang, Maggie [9 ]
Cross, Nancy [10 ]
Deherder, Delphine [9 ]
Gomez, Natalie Nunez [11 ]
Gottlieb, Alice B. [12 ]
机构：
[1] Sinclair Dermatol, East Melbourne, Vic, Australia
[2] Univ Lubeck, Lubeck, Germany
[3] Dermatrials Res Inc, Hamilton, ON, Canada
[4] Univ Amsterdam, Dept Dermatol, Med Ctr, Amsterdam, Netherlands
[5] Lausanne Univ Hosp, Dept Dermatol, Lausanne, Switzerland
[6] Southern Calif Dermatol, Santa Ana, CA USA
[7] Yale Univ, New Haven, CT USA
[8] Cent Connecticut Dermatol Res, Cromwell, CT USA
[9] UCB Pharma, Brussels, Belgium
[10] UCB, Morrisville, NC USA
[11] UCB Pharma, Monheim, Germany
[12] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Pariser, David
    Strober, Bruce
    Vanvoorden, Veerle
    Peterson, Luke
    Madden, Cynthia
    De Cuyper, Dirk
    Rubel, Diana
    Kimball, Alexa
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
  • [2] Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
    Thaci, Diamant
    Vender, Ron
    de Rie, Menno A.
    Conrad, Curdin
    Pariser, David M.
    Strober, Bruce
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    de Cuyper, Dirk
    Kimball, Alexa B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 22 - 31
  • [3] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
    Strober, Bruce
    Tada, Yayoi
    Mrowietz, Ulrich
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Warren, Richard B.
    Wang, Maggie
    Vanvoorden, Veerle
    Szilagyi, Balint
    Ciaravino, Valerie
    Paul, Carle
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 749 - 759
  • [4] Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial
    Leonardi, Craig
    Sator, Paul
    Morita, Akimichi
    Kokolakis, Georgios
    Blauvelt, Andrew
    Warren, Richard
    De Cuyper, Dirk
    Madden, Cynthia
    Vanvoorden, Veerle
    Wang, Maggie
    Foley, Peter
    Papp, Kim
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 13 - 14
  • [5] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Kim A. Papp
    Saskia de Vente
    Jiewei Zeng
    Mary Flack
    Byron Padilla
    Stephen K. Tyring
    [J]. Dermatology and Therapy, 2021, 11 : 487 - 497
  • [6] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    [J]. DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
  • [7] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Spelman, Lynda
    Eyerich, Kilian
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
  • [8] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [9] Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial
    Warren, Richard B.
    Strober, Bruce
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Davis, Leah
    Hoepken, Bengt
    Szilagyi, Balint
    Ciaravino, Valerie
    Bewley, Anthony
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [10] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Lebwohl, Mark
    Ghoreschi, Kamran
    Strober, Bruce
    Eyerich, Kilian
    Cather, Jennifer
    Wang, Maggie
    Cioffi, Christopher
    Deherder, Delphine
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Puig, Luis
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
12345